Literature DB >> 19533138

Antibodies directed to cyclic citrullinated peptides in familial Mediterranean fever.

Abdullah Uyanik1, Fatih Albayrak, M Hamidullah Uyanik, Hakan Dursun, Mustafa Keles, Ramazan Cetinkaya.   

Abstract

The aim of this study was to find the prevalence of anti-cyclic citrullinated peptide (anti-CCP) in patients with familial Mediterranean fever (FMF) and to examine the relationship between anti-CCP and joint findings. We measured the serum levels of the anti-CCP antibodies in patients with FMF (n = 55) and healthy controls (n = 43). Serum levels of rheumatoid factor (RF), erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), fibrinogen, ferritin, erythrocyte sedimentation rate (ESR), and white blood cell (WBC) were also measured in all the samples. Fibrinogen, ferritin, erythrocyte sedimentation rate (ESR), and RF levels were normal in the patient and the control groups (P > 0.05). There was a significant difference in anti-CCP between the patient and the control groups (P = 0.008). There was a positive correlation between arthritis and anti-CCP (P = 0.001). In patients without arthritis, there was no significant relationship between abdominal pain or fever and anti-CCP (P > 0.05). Anti-CCP levels increased in FMF patients with arthritis independent from acute phase reactants such as CRP, ESR, and fibrinogen. We conclude that in patients who are under investigation for arthritis, the ones with positive anti-CCP and negative RF, may be examined for FMF. In addition, we also conclude that it is very likely that FMF patients with anti-CCP antibodies will have signs of arthritis. On the other hand, it is possible that long-term follow-up of the FMF patients with anti-CCP antibodies may reveal the eventual development of inflammatory joint disease.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19533138     DOI: 10.1007/s00296-009-0993-5

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  22 in total

1.  Radiographic changes in the sacroiliac joints in familial Mediterranean fever.

Authors:  P A Brodey; S M Wolff
Journal:  Radiology       Date:  1975-02       Impact factor: 11.105

2.  Arthritis in children with familial Mediterranean fever.

Authors:  Erdal Ince; Nilgün Cakar; Mustafa Tekin; Tanil Kendirli; Nuray Ozkaya; Nejat Akar; Fatoş Yalçinkaya
Journal:  Rheumatol Int       Date:  2002-04       Impact factor: 2.631

3.  Antibodies against cyclic citrullinated peptide (CCP) in psoriatic patients with or without joint inflammation.

Authors:  G M Alenius; E Berglin; S Rantapää Dahlqvist
Journal:  Ann Rheum Dis       Date:  2005-08-11       Impact factor: 19.103

4.  Diagnostic accuracy of the anti-citrulline antibody assay for rheumatoid arthritis.

Authors:  N Bizzaro; G Mazzanti; E Tonutti; D Villalta; R Tozzoli
Journal:  Clin Chem       Date:  2001-06       Impact factor: 8.327

5.  Criteria for the diagnosis of familial Mediterranean fever.

Authors:  A Livneh; P Langevitz; D Zemer; N Zaks; S Kees; T Lidar; A Migdal; S Padeh; M Pras
Journal:  Arthritis Rheum       Date:  1997-10

6.  Antibodies to cyclic citrullinated peptides in psoriatic arthritis.

Authors:  Laura Bogliolo; Claudia Alpini; Roberto Caporali; Carlo Alberto Scirè; Remigio Moratti; Carlomaurizio Montecucco
Journal:  J Rheumatol       Date:  2005-03       Impact factor: 4.666

7.  Diagnostic performances of anti-cyclic citrullinated peptides antibody and antifilaggrin antibody in Korean patients with rheumatoid arthritis.

Authors:  Suk Woo Choi; Mi Kyoung Lim; Dong Hyuk Shin; Jeong Jin Park; Seung Cheol Shim
Journal:  J Korean Med Sci       Date:  2005-06       Impact factor: 2.153

8.  Anti-cyclic citrullinated peptide antibodies in rheumatoid arthritis and Behçet's disease.

Authors:  Suleyman Serdar Koca; Handan Akbulut; Sait Dag; Hakan Artas; Ahmet Isik
Journal:  Tohoku J Exp Med       Date:  2007-12       Impact factor: 1.848

9.  The clinical patterns of arthritis in children with familial Mediterranean fever.

Authors:  H A Majeed; M Rawashdeh
Journal:  QJM       Date:  1997-01

10.  A combination of autoantibodies to cyclic citrullinated peptide (CCP) and HLA-DRB1 locus antigens is strongly associated with future onset of rheumatoid arthritis.

Authors:  Ewa Berglin; Leonid Padyukov; Ulf Sundin; Göran Hallmans; Hans Stenlund; Walther J Van Venrooij; Lars Klareskog; Solbritt Rantapää Dahlqvist
Journal:  Arthritis Res Ther       Date:  2004-05-11       Impact factor: 5.156

View more
  6 in total

1.  Relapsing polychondritis and familial Mediterranean fever--an association.

Authors:  Edward B Miller; Joshua A Friedman; Yonatan Lahav; Zvi Landau
Journal:  Clin Rheumatol       Date:  2011-01-18       Impact factor: 2.980

2.  Anti-cyclic citrullinated Peptide frequency in patients with chronic hepatitis C virus infection and effect of presence of systemic disease.

Authors:  Ayse Albayrak; Hakan Dursun; Muhammet Hamidullah Uyanik; Serkan Cerrah
Journal:  Eurasian J Med       Date:  2012-12

3.  Anti-cyclic citrullinated peptide antibodies and joint involvement in Behçet's disease.

Authors:  Sung Bin Cho; Ju Hee Lee; Keun Jae Ahn; Byung Gi Bae; Taegyun Kim; Yong-Beom Park; Soo-Kon Lee; Kwang Hoon Lee; Dongsik Bang
Journal:  Yonsei Med J       Date:  2012-07-01       Impact factor: 2.759

4.  Anti-CCP antibody levels are not associated with MS: results from a case-control study.

Authors:  Mahmut Alpayci; Aysel Milanlioglu; Veysel Delen; Mehmet Nuri Aydin; Huseyin Guducuoglu; Yasemin Bayram
Journal:  Biomed Res Int       Date:  2015-02-02       Impact factor: 3.411

5.  Familial Mediterranean fever phenotype progression into anti-cyclic citrullinated peptide antibody-positive rheumatoid arthritis:a case report.

Authors:  Toru Yago; Tomoyuki Asano; Yuya Fujita; Kiyoshi Migita
Journal:  Fukushima J Med Sci       Date:  2020-11-06

6.  Anti-CCP Antibodies Are Not Associated with Familial Mediterranean Fever in Childhood.

Authors:  Hatice Onur; Hale Aral; Vefik Arica; Gamze Bercem; Murat Usta; Ozgur Kasapcopur
Journal:  Int J Rheumatol       Date:  2013-09-09
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.